FDA approves J&J’s nasal spray for treatment-resistant depression

The FDA has approved Johnson & Johnson‘s (NYSE:JNJ) esketamine nasal spray for people living with treatment-resistant depression.

The company’s product, Spravato, is an intranasal formulation of ketamine – a horse tranquilizer that is also known as Special K. The drug won support for approval from an FDA advisory committee earlier this year.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA approves J&J’s nasal spray for treatment-resistant depression appeared first on MassDevice.

from MassDevice https://ift.tt/2NL15dz